Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Tamoxifen

A selective oestrogen receptor modulator (SERM), synthesised in England in 1962 by chemist Dora Richardson: first marketed in the UK in 1973, it is a cornerstone of breast cancer treatment. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.

Did you know?It was born in a project for a contraceptive pill, but early studies showed it stimulated ovulation instead of suppressing it. In 1998 it became the first FDA-approved medicine to reduce the risk of breast cancer.

Tamoxifen CitrateGo to the active ingredient →
Tamoxifen-d5Isotopically labelledTamoxifen-d5Cat. No. P-T012-022CAS 157698-32-3

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.